The Weekly Summary

Stock-marketNovember 18th – November 24th  

In the general news, Iran and the U.S. struck a deal to curb Iran’s nuclear program. Critics said that it was simply a diversion by the Obama administration to drum up good news. Domestically, the stock markets continued to break new all-time highs as the Fed’s QE policies continue under Chairperson Yellen.

In healthcare business news, several M&A deals were announced. Cardiome (CRME) acquired Correvio LLC. CareFusion (CFN) acquired GE’s anesthesiology business, and Horizon Pharma (HRZB) acquired the rights to AZN‘s RA drug Vimovo.

On the data front, Amgen’s (AMGN), PCSK9 inhibitor cholesterol drug posted good 1-year data.

From the FDA, JNJ’s Olysio (simeprevir) for HCV was approved. Also, Bayer and Onyx’s (ONXX) Nexavar was approved for thyroid cancer.

In European regulatory news, Ariad’s (ARIA) leukemia drug, Iclusig, was approved to go back on the market after safety concerns halted sales, sending shares higher. Lastly, Biogen (BIIB) won a 10-year protection from generics for Tecfidera.

This entry was posted in - The Weekly Summary. Bookmark the permalink.

Leave a Reply

Your email address will not be published.